{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R%C2%AEII", "query": { "intervention": "M-M-R®II" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R%C2%AEII&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T16:39:34.375Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00617591", "title": "Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin (PLD)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2008-01", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617591" }, { "nct_id": "NCT03239873", "title": "Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Varicella" ], "interventions": [ { "name": "VARIVAX® PE34 Process", "type": "BIOLOGICAL" }, { "name": "VARIVAX® 2016 Commercial Process", "type": "BIOLOGICAL" }, { "name": "M-M-R II®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "23 Months", "sex": "ALL", "summary": "12 Months to 23 Months" }, "enrollment_count": 600, "start_date": "2017-10-17", "completion_date": "2019-04-02", "has_results": true, "last_update_posted_date": "2021-01-27", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03239873" }, { "nct_id": "NCT02766465", "title": "Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "r-ATG", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplant", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Standard of Care", "type": "PROCEDURE" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 138, "start_date": "2017-03-16", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 35, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02766465" }, { "nct_id": "NCT07222579", "title": "Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CD19 Positive", "Mixed Phenotype Acute Leukemia (MPAL)" ], "interventions": [ { "name": "Subcutaneous Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2026-01-15", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222579" }, { "nct_id": "NCT04333732", "title": "CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID 19" ], "interventions": [ { "name": "MR or M-M-R II ® vaccine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3411, "start_date": "2020-09-04", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2024-03-26", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04333732" }, { "nct_id": "NCT00392990", "title": "Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Regimen A", "type": "DRUG" }, { "name": "Regimen B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2007-02-06", "completion_date": "2013-05-28", "has_results": true, "last_update_posted_date": "2019-10-15", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 8, "location_summary": "Chicago, Illinois • Maywood, Illinois • Park Ridge, Illinois + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00392990" }, { "nct_id": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "GDC-0032", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 674, "start_date": "2011-03-16", "completion_date": "2021-06-25", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01296555" }, { "nct_id": "NCT00422292", "title": "Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Meningococcal Meningitis", "Measles", "Mumps", "Rubella", "Varicella" ], "interventions": [ { "name": "Meningococcal Polysaccharide Diphtheria Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Measles, Mumps, Rubella and Varicella", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "9 Months", "maximum_age": "12 Months", "sex": "ALL", "summary": "9 Months to 12 Months" }, "enrollment_count": 1664, "start_date": "2006-12", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2016-04-14", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 87, "location_summary": "Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Atascadero", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00422292" }, { "nct_id": "NCT00376961", "title": "S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 68, "start_date": "2006-08", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 147, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 95 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376961" }, { "nct_id": "NCT00263692", "title": "Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diphtheria", "Acellular Pertussis", "Tetanus" ], "interventions": [ { "name": "Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "4 Years to 6 Years" }, "enrollment_count": 401, "start_date": "2002-11", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2016-09-15", "last_synced_at": "2026-09-05T16:39:34.375Z", "location_count": 15, "location_summary": "Jonesboro, Arkansas • Fountain Valley, California • Oakland, California + 12 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00263692" } ] }